Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, have been published in Clinical Genitourinary Cancer.
The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
Discover more about how we help to shape the future of oncology treatments here.
Jump to a slide with the slide dots.
Inizio appoints Ryan Quigley as CEO to lead next phase of growth
We are delighted to announce the appointment of Ryan Quigley as Chief Executive Officer, effective 9 September 2025.
Read moreAccelerating impact in oncology at ESMO 2025
Meet Inizio at ESMO 2025 in Berlin to explore how oncology expertise and AI-driven insights advance cancer care.
Read moreInizio Medical and Inizio Evoke named finalists at 2025 Fierce Pharma Marketing Awards
We’re proud to announce that our teams across Inizio Medical and Inizio Evoke have been named finalists in three categories.
Read more